Classification Analysis of P-Glycoprotein Substrate Specificity

References

• Abel, S., Beaumont, K.C., Crespi, C.L., Eve, M.D., Fox, L., Hyland, R., Jones, B.C., Muirhead, G.J., Smith, D.A., Venn, R.F. and Walker, D.K. (2001) “Potential role for P-glycoprotein in the non- proportional pharmacokinetics of UK-343,664 in man”, Xenobiotica 31, 665–676.
   Google Scholar
• Abraham, M.H. (1993) “Scales of solute hydrogen-bonding: their construction and application to physicochemical and biochemical processes”, Chem. Soc. Rev. 22, 73–83.
   Web of Science ®Google Scholar
• Abraham, M.H. and Roses, M. (1994) “Hydrogen Bonding. 38. Effects of solute structure and mobile phase composition on reversed-phase high-performance liquid chromatographic capacity factors”, J. Phys. Org. Chem. 7, 672–684.
   Web of Science ®Google Scholar
• Abraham, M.H., Poole, C.F. and Poole, S.K. (1996) “Solute effects on reversed-phase thin-layer chromatography. A linear free energy relationship analysis”, J. Chromatogr. 749, 201–209.
   Web of Science ®Google Scholar
• Abraham, M.H., Chadha, H.S., Martins, F., Mitchell, R.C., Bradbury, M.W. and Gratton, J.A. (1999) “Hydrogen bonding part 46: a review of the correlation and prediction of transport properties by an LFER method: physicochemical properties, brain penetration and skin permeability”, Pestic. Sci. 55, 78–88.
   Google Scholar
• Adachi, Y., Suzuki, H. and Sugiyama, Y. (2001) “Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-Glycoprotein”, Pharm. Res. 18, 1660–1668.
   PubMed Web of Science ®Google Scholar
• Aksentijevich, I., Cardarelli, C.O., Pastan, I. and Gottesman, M.M. (1996) “Retroviral transfer of the human MDR1 gene confers resistance to bisantrene-specific hematotoxicity”, Clin. Cancer Res. 2, 973–980.
   PubMed Web of Science ®Google Scholar
• Ambudkar, S.V., Dey, S., Hrycyna, C.A., Ramachandra, M., Pastan, I. and Gottesman, M.M. (1999) “Biochemical, cellular, and pharmaco- logical aspects of the multidrug transporter”, Annu Rev. Pharmacol. Toxicol 39, 361–398.
   PubMed Web of Science ®Google Scholar
• Ayesh, S., Shao, Y.M. and Stein, W.D. (1996) “Co-operative, competitive and non-competitive interactions between modulators of P-glyco- protein”, Biochim. Biophys. Acta 1316, 8–18.
   PubMed Web of Science ®Google Scholar
• Ayrton, A. and Morgan, P. (2001) “Role of transport proteins in drug absorption, distribution and excretion”, Xenobiotica 31, 469–497.
   PubMed Web of Science ®Google Scholar
• Bacher, G., Nickel, B., Emig, P., Vanhoefer, U., Seeber, S., Shandra, A., Klenner, T. and Beckers, T. (2001) “D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity”, Cancer Res. 61, 392–399.
   PubMed Web of Science ®Google Scholar
• Bain, L.J. and LeBlanc, G.A. (1996) “Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein”, Toxicol. Appl. Pharmacol. 141, 288–298.
   PubMed Web of Science ®Google Scholar
• Bakken, G.A. and Jurs, P.C. (2000) “Classification of multidrug- resistance reversal agents using structure-based descriptors and linear discriminant analysis”, J. Med. Chem. 43, 4534–4541.
   PubMed Web of Science ®Google Scholar
• Barecki-Roach, M., Wang, E.J. and Johnson, W.W. (2003) “Many P-glycoprotein substrates do not inhibit the transport process across cell membranes”, Xenobiotica 33, 131–140.
   PubMed Web of Science ®Google Scholar
• Barnes, K.M., Dickstein, B., Cutler, G.B. Jr., Fojo, T. and Bates, S.E. (1996) “Steroid treatment, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells”, Biochemistry 35, 4820–4827.
   PubMed Web of Science ®Google Scholar
• Begley, D.J., Lechardeur, D., Chen, Z.D., Rollinson, C., Bardoul, M. and Roux, F., Scherman, D., Abbott, N.J. (1996) “Functional expression of P-glycoprotein in an immortalised cell line of rat brain endothelial cells, RBE4”, J. Neurochem. 67, 988–995.
   PubMed Web of Science ®Google Scholar
• Borgnia, M.J., Eytan, G.D. and Assaraf, Y.G. (1996) “Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity”, J. Biol. Chem. 271, 3163–3171.
   PubMed Web of Science ®Google Scholar
• Callaghan, R. and Higgins, C.F. (1995) “Interaction of tamoxifen with the multidrug resistance P-glycoprotein”, Br. J. Cancer 71, 294–299.
   PubMed Web of Science ®Google Scholar
• Chen, W., Yang, J.Z., Andersen, R., Nielsen, L.H. and Borchardt, R.T. (2002) “Evaluation of the permeation characteristics of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs across the blood-brain barrier using an in situ perfused rat brain model”, J. Pharmacol. Exp. Ther. 303, 849-857. Chen, C., Hanson, E., Watson, J.W. and Lee, J.S. (2003) “P-Glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists”, Drug Metab. <i>Dispos 31, 312–318.
   Google Scholar
• Chiba, P., Ecker, G., Schmid, D., Drach, J., Tell, B., Goldenberg, S. and Gekeler, V. (1996) “Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance”, Mol. Pharmacol. 49, 1122–1130.
   PubMed Web of Science ®Google Scholar
• Chishty, M., Reichel, A., Siva, J., Abbott, N.J. and Begley, D.J. (2001) “Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines”, J. Drug Target. 9, 223–228.
   PubMed Web of Science ®Google Scholar
• Cisternino, S., Rousselle, C., Dagenais, C. and Scherrmann, J.M. (2001) “Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice”, Pharm. Res. 18, 183–190.
   PubMed Web of Science ®Google Scholar
• Cummins, C.L., Jacobsen, W. and Benet, L.Z. (2002) “Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4”, J. Pharmacol. Exp. Ther. 300, 1036–1045.
   PubMed Web of Science ®Google Scholar
• Cvetkovic, M., Leake, B., Fromm, M.F., Wilkinson, G.R. and Kim, R.B. (1999) “OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine”, Drug Metab. Dispos. 27, 866–871.
   PubMed Web of Science ®Google Scholar
• Dagenais, C., Ducharme, J. and Pollack, G.M. (2001a) “Uptake and efflux of the peptidic delta-opioid receptor agonist”, Neurosci. Lett. 301, 155–158.
   PubMed Web of Science ®Google Scholar
• Dagenais, C., Zong, J., and Pollack, G.M. (2001b) “Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds”, Pharm. Res. 18, 957–963.
   PubMed Web of Science ®Google Scholar
• Dai, H., Marbach, P., Lemaire, M., Hayes, M. and Elmquist, W.F. (2003) “Distribution of STI-571 to the brain is limited by P-glycoprotein- mediated efflux”, J. Pharmacol. Exp. Ther. 304(3),1085–1092.
   PubMed Web of Science ®Google Scholar
• Dantzig, A.H., Shepard, R.L., Law, K.L., Tabas, L., Pratt, S., Gillespie, J.S., Binkley, S.N., Kuhfeld, M.T., Starling, J.J. and Wrighton, S.A. (1999) “Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities”, J. Pharmacol. Exp. Ther. 290, 854–862.
   PubMed Web of Science ®Google Scholar
• van Der Kaaden, J.E., Hemscheidt, T.K. and Mooberry, S.L. (2001) “Mappain, a new cytotoxic prenylated stilbene from Macaranga mappa”, J. Nat. Prod. 64, 103–105.
   PubMed Web of Science ®Google Scholar
• Dey, S., Ramachandra, M., Pastan, I., Gottesman, M.M. and Ambudkar, S.V. (1997) “Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein”, Proc. Natl Acad. Sci. USA 94, 10594–10599.
   PubMed Web of Science ®Google Scholar
• Doan, K.M., Humphreys, J.E., Webster, L.O., Wring, S.A., Shampine, L.J., Serabjit-Singh, C.J., Adkison, K.K. and Polli, J.W. (2002) “Passive permeability and P-glycoprotein-mediated efflux differen- tiate central nervous system (CNS) and non-CNS marketed drugs”, J. Pharmacol. Exp. Ther. 303, 1029–1037.
   PubMed Web of Science ®Google Scholar
• Doppenschmitt, S., Spahn-Langguth, H., Regardh, C.G. and Langguth, P. (1999) “Role of P-glycoprotein-mediated secretion in absorptive drug permeability: an approach using passive membrane permeability and affinity to P-glycoprotein”, J. Pharm. Sci. 88, 1067–1072.
   PubMed Web of Science ®Google Scholar
• Ecker, G., Chiba, P., Hitzler, M., Schmid, D., Visser, K., Cordes, H.P., Csollei, J., Seydel, J.K. and Schaper, K.J. (1996) “Structure-activity relationship studies on benzofuran analogs of propafenone-type modulators of tumor cell multidrug resistance”, J. Med. Chem. 39, 4767–4774.
   PubMed Web of Science ®Google Scholar
• Ecker, G., Huber, M., Schmid, D. and Chiba, P. (1999) “The importance of a nitrogen atom in modulators of multidrug resistance”, Mol. Pharmacol. 56, 791–796.
   PubMed Web of Science ®Google Scholar
• Ekins, S., Kim, R.B., Leake, B.F., Dantzig, A.H., Schuetz, E.G., Lan, L.B., Yasuda, K., Shepard, R.L., Winter, M.A., Schuetz, J.D., Wikel, J.H. and Wrighton, S.A. (2002a) “Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates”, Mol. Pharmacol. 61, 974–981.
   PubMed Web of Science ®Google Scholar
• Ekins, S., Kim, R.B., Leake, B.F., Dantzig, A.H., Schuetz, E.G., Lan, L.B., Yasuda, K., Shepard, R.L., Winter, M.A., Schuetz, J.D., Wikel, J.H. and Wrighton, S.A. (2002b) “Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein”, Mol. Pharmacol. 61, 964–973.
   PubMed Web of Science ®Google Scholar
• Eneroth, A., Astrom, E., Hoogstraate, J., Schrenk, D., Conrad, S., Kauffmann, H.M. and Gjellan, K. (2001) “Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction”, Eur. J. Pharm. Sci. 12, 205–214.
   PubMed Web of Science ®Google Scholar
• Ertl, P., Rohde, B. and Selzer, P. (2000) “Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”, J. Med. Chem. 43, 3714–3717.
   PubMed Web of Science ®Google Scholar
• Essodaigui, M., Broxterman, H.J. and Garnier-Suillerot, A. (1998) “Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein”, Biochemistry 37, 2243–2250.
   PubMed Web of Science ®Google Scholar
• Etievant, C., Barret, J.M., Kruczynski, A., Perrin, D. and Hill, B.T. (1998) “Vinflunine (200,200 -difluoro-30,40 -dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro”, Invest. New Drugs 16, 3–17.
   PubMed Web of Science ®Google Scholar
• Eytan, G.D., Regev, R., Oren, G. and Assaraf, Y.G. (1996) “The role of passive transbilayer drug movement in multidrug resistance and its modulation”, J. Biol. Chem. 271, 12897–12902.
   PubMed Web of Science ®Google Scholar
• Faber, K.N., Muller, M. and Jansen, P.L. (2003) “Drug transport proteins in the liver”, Adv. Drug Deliv. Rev. 55(1),107–124.
   PubMed Web of Science ®Google Scholar
• Ferte, J. (2000) “Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane”, Eur. J. Biochem. 267, 277–294.
   PubMedGoogle Scholar
• Garrigues, A., Loiseau, N., Delaforge, M., Ferte, J., Garrigos, M., Andre, F. and Orlowski, S. (2002) “Characterization of two pharmacophores on the multidrug transporter P-glycoprotein”, Mol. Pharmacol 62, 1288–1298.
   PubMed Web of Science ®Google Scholar
• Glynn, S.L. and Yazdanian, M. (1998) “In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents”, J. Pharm. Sci. 87, 306–310.
   PubMed Web of Science ®Google Scholar
• Gottesman, M.M., Fojo, T. and Bates, S.E. (2002) “Multidrug resistance in cancer: role of ATP-dependent transporters”, Nat. Rev. Cancer 2, 48–58.
   PubMed Web of Science ®Google Scholar
• Gourdeau, H., Genne, P., Kadhim, S., Bibeau, L., Duchamp, O., Ouellet, F., DeMuys, J.M., Bouffard, D.Y. and Attardo, G. (2002) “Antitumor activity of troxacitabine (Troxatyl) against anthracycline- resistant human xenografts”, Cancer Chemother. Pharmacol. 50, 490–496.
   PubMed Web of Science ®Google Scholar
• Gros, P., Talbot, F., Tang-Wai, D., Bibi, E. and Kaback, H.R. (1992) “Lipophilic cations: a group of model substrates for the multidrug- resistance transporter”, Biochemistry 31, 1992–1998.
   PubMed Web of Science ®Google Scholar
• Hamilton, K.O., Backstrom, G., Yazdanian, M.A. and Audus, K.L. (2001) “P-glycoprotein efflux pump expression and activity in Calu-3 cells”, J. Pharm. Sci. 90, 647–658.
   PubMed Web of Science ®Google Scholar
• Hansch, C., Kurup, A., Garg, R. and Gao, H. (2001) “Chem-Informatics and QSAR: a review of QSAR lacking positive hydrophobic terms”, Chem. Rev. 101, 619–672.
   PubMed Web of Science ®Google Scholar
• Hiessbock, R., Wolf, C., Richter, E., Hitzler, M., Chiba, P., Kratzel, M. and Ecker, G. (1999) “Synthesis and in vitro multidrug resistance modulating activity of a series of dihydrobenzopyrans and tetrahydroquinolines”, J. Med. Chem. 42, 1921–1926.
   PubMed Web of Science ®Google Scholar
• Horio, M., Chin, K.V., Currier, S.J., Goldenberg, S., Williams, C., Pastan, I., Gottesman, M.M. and Handler, J. (1989) “Transepithelial transport of drugs by the multidrug transporter in cultured Madin-Darby canine kidney cell epithelia”, J. Biol. Chem. 264, 14880–14884.
   PubMed Web of Science ®Google Scholar
• Hunter, J., Hirst, B.H. and Simmons, N.L. (1993) “Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers”, Pharm. Res. 10, 74–749.
   Google Scholar
• Ishikawa, T., Muller, M., Klunemann, C., Schaub, T. and Keppler, D. (1990) “ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates”, J. Biol. Chem. 265, 19279–19286.
   PubMed Web of Science ®Google Scholar
• Ito, T., Yano, I., Tanaka, K. and Inui, K.I. (1997) “Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1”, J. Pharmacol. Exp. Ther. 282, 955–960.
   PubMed Web of Science ®Google Scholar
• Japertas, P., Didziapetris, R. and Petrauskas, A. (2002) “Fragmental methods in the design of new compounds. Applications of advanced algorithm builder”, Quant. Struct.–Act. Relat. 21, 23–37.
   Web of Science ®Google Scholar
• Japertas, P., Didziapetris, R. and Petrauskas, A. (2003) “Fragmental methods in the analysis of biological activities of diverse compound sets”, Curr. Mini-Rev. Med. Chem. 3, 797–803.
   PubMedGoogle Scholar
• Jonker, J.W., Wagenaar, E., van Deemter, L., Gottschlich, R., Bender, H.M., Dasenbrock, J. and Schinkel, A.H. (1999) “Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug”, Br. J. Pharmacol. 127, 43–50.
   PubMed Web of Science ®Google Scholar
• Karlsson, J., Kuo, S.M., Ziemniak, J. and Artursson, P. (1993) “Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein”, Br. J. Pharmacol. 110, 1009–1016.
   PubMed Web of Science ®Google Scholar
• Kavallaris, M., Madafiglio, J., Norris, M.D. and Haber, M. (1993) “Resistance to tetracycline, a hydrophilic antibiotic, is mediated by P-glycoprotein in human multidrug-resistant cells”, Biochem. Biophys. Res. Commun. 190, 79–85.
   PubMed Web of Science ®Google Scholar
• Kerns, E.H. and Di, L. (2003) “Pharmaceutical profiling in drug discovery”, Drug Discov. Today 8, 316–323.
   PubMed Web of Science ®Google Scholar
• Kessel, D., Beck, W.T., Kukuruga, D. and Schulz, V. (1991) “Characterization of multidrug resistance by fluorescent dyes”, Cancer Res. 51, 4665–4670.
   PubMed Web of Science ®Google Scholar
• Kim, R.B. (2002) “Drugs as P-glycoprotein substrates, inhibitors, and inducers”, Drug Metab. Rev. 34, 47–54.
   PubMed Web of Science ®Google Scholar
• Kim, R.B., Fromm, M.F., Wandel, C., Leake, B., Wood, A.J., Roden, D.M. and Wilkinson, G.R. (1998) “The drug transporter P-glyco- protein limits oral absorption and brain entry of HIV-1 protease inhibitors”, J. Clin. Investig 101, 289–294.
   PubMed Web of Science ®Google Scholar
• Kim, R.B., Wandel, C., Leake, B., Cvetkovic, M., Fromm, M.F., Dempsey, P.J., Roden, M.M., Belas, F., Chaudhary, A.K., Roden, D.M., Wood, A.J. and Wilkinson, G.R. (1999) “Interrelationship between substrates and inhibitors of human CYP3A, P-glycoprotein”, Pharm. Res. 16, 408–414.
   PubMed Web of Science ®Google Scholar
• Klopman, G., Shi, L.M. and Ramu, A. (1997) “Quantitative structure-activity relationship of multidrug resistance reversal agent”, Mol. Pharmacol. 52, 323–334.
   PubMed Web of Science ®Google Scholar
• Kubinyi, H. (1997) “QSAR and 3D QSAR in drug design. Part 2: applications and problems”, Drug Discovery Today 2, 538–546.
   Google Scholar
• Kubinyi, H. (1998) “Comparative molecular field analysis (CoMFA)”, In: Schleyer, P.V.R., Allinger, N.L., Clark, T., Gasteiger, J., Kollman, P.A., Schaefer, III, H.F. and Schreiner, P.R., eds, The Encyclopedia of Computational Chemistry 4, pp 449–460.
   Google Scholar
• Kumar, S., Kwei, G.Y., Poon, G.K., Iliff, S.A., Wang, Y., Chen, Q., Franklin, R.B., Didolkar, V., Wang, R.W., Yamazaki, M., Chiu, S.H., Lin, J.H., Pearson, P.G. and Baillie, T.A. (2003) “Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein”, J. Pharmacol. Exp. Ther. 304, 1161–1171.
   PubMed Web of Science ®Google Scholar
• Lang, V.B., Langguth, P., Ottiger, C., Wunderli-Allenspach, H., Rognan, D., Rothen-Rutishauser, B., Perriard, J.C., Lang, S., Biber, J. and Merkle, H.P. (1997) “Structure-permeation relations of met-enkephalin peptide analogues on absorption and secretion mechanisms in Caco-2 monolayers”, J. Pharm Sci. 86, 846–853.
   PubMed Web of Science ®Google Scholar
• de Lange, E.C., Marchand, S., van den Berg, D., van der Sandt, I.C., de Boer, A.G., Delon, A., Bouquet, S. and Couet, W. (2000) “In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of spar- floxacin”, Eur. J. Pharm. Sci. 12, 85–93.
   PubMed Web of Science ®Google Scholar
• Lankas, G.R., Cartwright, M.E. and Umbenhauer, D. (1997) “P-glyco- protein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity”, Toxicol. Appl. Pharmacol. 143, 357–365.
   PubMed Web of Science ®Google Scholar
• Lee, J.S., Paull, K., Alvarez, M., Hose, C., Monks, A., Grever, M., Fojo, A.T. and Bates, S.E. (1994) “Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen”, Mol. Pharmacol. 46, 627–638.
   PubMed Web of Science ®Google Scholar
• Lee, K., Ng, C., Brouwer, K.L. and Thakker, D.R. (2002) “Secretory transport of ranitidine and famotidine across Caco-2 cell mono- layers”, J. Pharmacol. Exp. Ther. 303, 574–580.
   PubMed Web of Science ®Google Scholar
• Leusch, A., Volz, A., Muller, G., Wagner, A., Sauer, A., Greischel, A. and Roth, W. (2002) “Altered drug disposition of the platelet activating factor antagonist apafant in mdr1a knockout mice”, Eur. J. Pharm. Sci. 16, 119–128.
   PubMed Web of Science ®Google Scholar
• Liang, E., Proudfoot, J. and Yazdanian, M. (2000) “Mechanisms of transport and structure-permeability relationship of sulfasalazine and its analogs in Caco-2 cell monolayers”, Pharm. Res. 17, 1168–1174.
   PubMed Web of Science ®Google Scholar
• Lin, J.H. (2003) “Drug-drug interaction mediated by inhibition and induction of P-glycoprotein”, Adv. Drug Deliv. Rev. 55, 53–81.
   PubMed Web of Science ®Google Scholar
• Lin, J.H. and Yamazaki, M. (2003) “Role of P-glycoprotein in pharmacokinetics: clinical implications”, Clin. Pharmacokinet. 42, 59–98.
   PubMed Web of Science ®Google Scholar
• Litman, T., Zeuthen, T., Skovsgaard, T. and Stein, W.D. (1997) “Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity”, Biochim. Biophys. Acta 1361, 159–168.
   PubMed Web of Science ®Google Scholar
• Maeng, H.J., Yoo, H.J., Kim, I.W., Song, I.S., Chung, S.J. and Shim, C.K. (2002) “P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers”, J. Pharm. Sci. 91, 2614–2621.
   PubMed Web of Science ®Google Scholar
• Martin, C., Berridge, G., Higgins, C.F., Mistry, P., Charlton, P. and Callaghan, R. (2000a) “Communication between multiple drug binding sites on P-glycoprotein”, Mol. Pharmacol 58, 624–632.
   PubMed Web of Science ®Google Scholar
• Martin, C., Berridge, G., Mistry, P., Higgins, C.F., Charlton, P. and Callaghan, R. (2000b) “Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis”, Biochemistry 39, 11901–11906.
   PubMed Web of Science ®Google Scholar
• Martin, C., Higgins, C.F. and Callaghan, R. (2001) “The vinblastine binding site adopts high- and low-affinity conformations during a transport cycle of P-glycoprotein”, Biochemistry 40, 15733–15742.
   PubMed Web of Science ®Google Scholar
• Matsuzaki, J., Yamamoto, C., Miyama, T., Takanaga, H., Matsuo, H., Ishizuka, H., Kawahara, Y., Kuwano, M., Naito, M., Tsuruo, T. and Sawada, Y. (1999) “Contribution of P-glycoprotein to unitrolol efflux across blood-brain barrier”, Biopharm. Drug Dispos. 20, 85–90.
   PubMed Web of Science ®Google Scholar
• von Moltke, L.L. and Greenblatt, D.J. (2000) “Drug transporters in psychopharmacology—are they important?”, J. Clin. Psychopharmacol. 20, 291–294.
   PubMed Web of Science ®Google Scholar
• Norinder, U. and Haeberlein, M. (2002) “Computational approaches to the prediction of the blood-brain distribution”, Adv. Drug Deliv. Rev. 54, 291–313.
   PubMed Web of Science ®Google Scholar
• Osterberg, T. and Norinder, U. (2000) “Prediction of polar surface area and drug transport processes using simple parameters and PLS statistics”, J. Chem. Inf. Comput. Sci. 40, 1408–1411.
   PubMedGoogle Scholar
• Pajeva, I.K. and Wiese, M. (2002) “Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis)”, J. Med. Chem. 45, 5671–5686.
   PubMed Web of Science ®Google Scholar
• Pascaud, C., Garrigos, M. and Orlowski, S. (1998) “Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents”, Biochem. J. 333, 351–358.
   PubMed Web of Science ®Google Scholar
• Pauli-Magnus, C., von Richter, O., Burk, O., Ziegler, A., Mettang, T., Eichelbaum, M. and Fromm, M.F. (2000) “Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein”, J. Pharmacol. Exp. Ther. 293, 376–382.
   PubMed Web of Science ®Google Scholar
• Pauli-Magnus, C., Murdter, T., Godel, A., Mettang, T., Eichelbaum, M., Klotz, U. and Fromm, M.F. (2001a) “P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin”, Naunyn Schmiedebergs Arch. Pharmacol. 363, 337–343.
   PubMed Web of Science ®Google Scholar
• Pauli-Magnus, C., Rekersbrink, S., Klotz, U. and Fromm, M.F. (2001b) “Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein”, Naunyn Schmiedebergs Arch. Pharmacol. 364, 551–557.
   PubMed Web of Science ®Google Scholar
• Penzotti, J.E., Lamb, M.L., Evensen, E. and Grootenhuis, P.D. (2002) “A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein”, J. Med. Chem. 45, 1737–1740.
   PubMed Web of Science ®Google Scholar
• Platts, J.A., Butina, D., Abraham, M.H. and Hersey, A. (1999) “Estimation of molecular linear free energy relationship descriptors using a group contribution approach”, J. Chem. Inf. Comput. Sci. 39, 835–845.
   Google Scholar
• Polli, J.W., Wring, S.A., Humphreys, J.E., Huang, L., Morgan, J.B., Webster, L.O. and Serabjit-Singh, C.S. (2001) “Rational use of in vitro P-glycoprotein assays in drug discovery”, J. Pharmacol. Exp. Ther. 299, 620–628.
   PubMed Web of Science ®Google Scholar
• Prueksaritanont, T., Meng, Y., Ma, B., Leppert, P., Hochman, J., Tang, C., Perkins, J., Zrada, M., Meissner, R., Duggan, M.E. and Lin, J.H. (2002) “Differences in the absorption, metabolism and biliary excretion of a diastereomeric pair of alphavbeta3-antagonists in rat: limited role of P-glycoprotein”, Xenobiotica 32, 207–220.
   PubMed Web of Science ®Google Scholar
• Rosenberg, M.F., Callaghan, R., Ford, R.C. and Higgins, C.F. (1997) “Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis”, J. Biol. Chem. 272, 10685–10694.
   PubMed Web of Science ®Google Scholar
• Rosenberg, M.F., Kamis, A.B., Callaghan, R., Higgins, C.F. and Ford, R.C. (2003) “Three-dimensional structures of the mammalian multidrug resistance P-glycoprotein demonstrate major confor- mational changes in the transmembrane domains upon nucleotide binding”, J. Biol. Chem. 278, 8294–8299.
   PubMed Web of Science ®Google Scholar
• Saeki, T., Ueda, K., Tanigawara, Y., Hori, R. and Komano, T. (1993a) “P-glycoprotein-mediated transcellular transport of MDR-reversing agents”, FEBS Lett. 324, 99–102.
   PubMed Web of Science ®Google Scholar
• Saeki, T., Ueda, K., Tanigawara, Y., Hori, R. and Komano, T. (1993b) “Human P-glycoprotein transports cyclosporin A and FK506”, J. Biol. Chem. 268, 6077–6080.
   PubMed Web of Science ®Google Scholar
• Saitoh, H. and Aungst, B.J. (1995) “Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine”, Pharm. Res. 12, 1304–1310.
   PubMed Web of Science ®Google Scholar
• Saitoh, H., Gerard, C. and Aungst, B.J. (1996) “The secretory intestinal transport of some beta-lactam antibiotics and anionic compounds: a mechanism contributing to poor oral absorption”, J. Pharmacol. Exp. Ther. 278, 205–211.
   PubMed Web of Science ®Google Scholar
• Saitoh, H., Hatakeyama, M., Eguchi, O., Oda, M. and Takada, M. (1998) “Involvement of intestinal P-glycoprotein in the restricted absorption of methylprednisolone from rat small intestine”, J. Pharm. Sci. 87, 73–75.
   PubMed Web of Science ®Google Scholar
• van der Sandt, I.C., Smolders, R., Nabulsi, L., Zuideveld, K.P., de Boer, A.G. and Breimer, D.D. (2001) “Active efflux of the 5-HT(1A) receptor agonist flesinoxan via P-glycoprotein at the blood-brain barrier”, Eur. J. Pharm. Sci. 14, 81–86.
   PubMed Web of Science ®Google Scholar
• Sarkadi, B., Price, E.M., Boucher, R.C., Germann, U.A. and Scarborough, G.A. (1992) “Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug- stimulated membrane ATPase”, J. Biol. Chem. 267, 4854–4858.
   PubMed Web of Science ®Google Scholar
• Sawamoto, T., Van Gelder, T., Christians, U., Okamura, N., Jacobsen, W. and Benet, L. (2001) “Membrane transport of mycophenolate mofetil and its active metabolite, mycophenolic acid in MDCK and MDR1- MDCK cell monolayers”, J. Heart Lung Transplant. 20, 234–235.
   PubMedGoogle Scholar
• Scala, S., Akhmed, N., Rao, U.S., Paull, K., Lan, L.B., Dickstein, B., Lee, J.S., Elgemeie, G.H., Stein, W.D. and Bates, S.E. (1997) “P-glycoprotein substrates and antagonists cluster into two distinct groups”, Mol. Pharmacol. 51, 1024–1033.
   PubMed Web of Science ®Google Scholar
• Schinkel, A.H. (1999) “P-glycoprotein, a gatekeeper in the blood-brain barrier”, Adv. Drug Deliv. Rev. 36, 179–194.
   PubMed Web of Science ®Google Scholar
• Schinkel, A.H. and Jonker, J.W. (2003) “Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview”, Adv. Drug Deliv. Rev. 55, 3–29.
   PubMed Web of Science ®Google Scholar
• Schinkel, A.H., Smit, J.J., van Tellingen, O., Beijnen, J.H., Wagenaar, E., van Deemter, L., Mol, C.A., van der Valk, M.A., Robanus-Maandag, E.C., te Riele, H.P., Berns, A.J.M. and Borst, P. (1994) “Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs”, Cell 77, 491–502.
   PubMed Web of Science ®Google Scholar
• Schinkel, A.H., Wagenaar, E., van Deemter, L., Mol, C.A. and Borst, P. (1995) “Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A”, J. Clin. Investig. 96, 1698–1705.
   PubMed Web of Science ®Google Scholar
• Schinkel, A.H., Wagenaar, E., Mol, C.A. and van Deemter, L. (1996) “P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs”, J. Clin. Investig. 97, 2517–2524.
   PubMed Web of Science ®Google Scholar
• Schmid, D., Ecker, G., Kopp, S., Hitzler, M. and Chiba, P. (1999) “Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements”, Biochem. Pharmacol. 58, 1447–1456.
   PubMed Web of Science ®Google Scholar
• Schwab, D., Fischer, H., Tabatabaei, A., Poli, S. and Huwyler, J. (2003) “Comparison of in vitro p-glycoprotein screening assays: recommendations for their use in drug discovery”, J. Med. Chem. 46, 1716–1725.
   PubMed Web of Science ®Google Scholar
• Seelig, A. (1998) “A general pattern for substrate recognition by P-glycoprotein”, Eur. J. Biochem. 251, 252–261.
   PubMedGoogle Scholar
• Seelig, A. and Landwojtowicz, E. (2000) “Structure-activity relationship of P-glycoprotein substrates and modifiers”, Eur. J. Pharm. Sci. 12, 31–40.
   PubMed Web of Science ®Google Scholar
• Seelig, A., Landwojtowicz, E., Fisher, H. and Li Blatter, X. (2003) “Towards P-glycoprotein structure-activity relationships”, In: Van der Waterbeemd, Lennernas and Arthurson, eds, Drug BioAvailabil- ity/Estimation of Solubility, Permeability and Absorption, pp 461–492.
   Google Scholar
• Selassie, C.D., Hansch, C. and Khwaja, T.A. (1990) “Structure-activity relationships of antineoplastic agents in multidrug resistance”, J. Med. Chem. 33, 1914–1919.
   PubMed Web of Science ®Google Scholar
• Shapiro, A.B. and Ling, V. (1997) “Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities”, Eur. J. Biochem. 250, 130–137.
   PubMedGoogle Scholar
• Sharma, R.P., Bhandari, N., Tsunoda, M., Riley, R.T., Voss, K.A. and Meredith, F.I. (2000) “Fumonisin toxicity in a transgenic mouse model lacking the mdr1a/1b P-glycoprotein genes”, Environ. Toxicol. Pharmacol. 8, 173–182.
   PubMed Web of Science ®Google Scholar
• Sharom, F.J. (1997) “The P-glycoprotein efflux pump: how does it transport drugs?”, J. Membr. Biol. 160, 161–175.
   PubMed Web of Science ®Google Scholar
• Sharom, F.J., Yu, X., DiDiodato, G. and Chu, J.W. (1996) “Synthetic hydrophobic peptides are substrates for P-glycoprotein and stimulate drug transport”, Biochem. J. 320, 421–428.
   PubMed Web of Science ®Google Scholar
• Sills, G.J., Kwan, P., Butler, E., de Lange, E.C., van den Berg, D.J. and Brodie, M.J. (2002) “P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice”, Epilepsy Behav. 3, 427–432.
   PubMed Web of Science ®Google Scholar
• Spahn-Langguth, H., Baktir, G., Radschuweit, A., Okyar, A., Terhaag, B., Ader, P., Hanafy, A. and Langguth, P. (1998) “P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound”, Int. J. Clin. Pharmacol. Ther. 36, 16–24.
   PubMed Web of Science ®Google Scholar
• Stormer, E., von Moltke, L.L., Perloff, M.D. and Greenblatt, D.J. (2001) “P-glycoprotein interactions of nefazodone and trazodone in cell culture”, J. Clin. Pharmacol. 41, 708–714.
   PubMed Web of Science ®Google Scholar
• Stormer, E., von Moltke, L.L., Perloff, M.D. and Greenblatt, D.J. (2002) “Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture”, Pharm. Res. 19, 1038–1045.
   PubMed Web of Science ®Google Scholar
• Stouch, T.R. and Gudmundsson, O. (2002) “Progress in understanding the structure-activity relationships of P-glycoprotein”, Adv. Drug Deliv. Rev. 54, 315–328.
   PubMed Web of Science ®Google Scholar
• Susanto, M. and Benet, L.Z. (2002) “Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport?”, Pharm. Res. 19, 457–462.
   PubMed Web of Science ®Google Scholar
• Takara, K., Tanigawara, Y., Komada, F., Nishiguchi, K., Sakaeda, T. and Okumura, K. (2000) “The novel anticancer drug KRN5500 interacts with, but is hardly transported by, human P-glycoprotein”, Jpn J. Cancer Res. 91, 248–254.
   PubMedGoogle Scholar
• Takara, K., Sakaeda, T., Yagami, T., Kobayashi, H., Ohmoto, N., Horinouchi, M., Nishiguchi, K. and Okumura, K. (2002) “Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines”, Biol. Pharm. Bull. 25, 771–778.
   PubMed Web of Science ®Google Scholar
• Tamai, I., Kido, Y., Yamashita, J., Sai, Y. and Tsuji, A. (2002) “Blood-brain barrier transport of H1-antagonist ebastine and its metabolite carebastine”, J. Drug Target. 8, 383–393.
   Web of Science ®Google Scholar
• Tang, F. and Borchardt, R.T. (2002) “Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE”, Pharm. Res. 19, 787–793.
   PubMed Web of Science ®Google Scholar
• Tanigawara, Y., Okamura, N., Hirai, M., Yasuhara, M., Ueda, K., Kioka, N., Komano, T. and Hori, R. (1992) “Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1)”, J. Pharmacol. Exp. Ther. 263, 840–845.
   PubMed Web of Science ®Google Scholar
• Terao, T., Hisanaga, E., Sai, Y., Tamai, I. and Tsuji, A. (1996) “Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier”, J. Pharm. Pharmacol. 48, 1083–1089.
   PubMed Web of Science ®Google Scholar
• Testa, B., Crivori, P., Reist, M. and Carrupt, P.A. (2000) “The Influence of lipophilicity on the pharmacokinetic behaviour of drugs: concepts and examples”, Persp. Drug Disc. Design 19, 179–211.
   Web of Science ®Google Scholar
• Thompson, S.J., Koszdin, K. and Bernards, C.M. (2000) “Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein”, Anesthesiology 92, 1392–1399.
   PubMed Web of Science ®Google Scholar
• Tkaczyk-Gobis, K., Tarasiuk, J., Seksek, O., Stefanska, B., Borowski, E. and Garnier-Suillerot, A. (2001) “Transport of new non-cross- resistant antitumor compounds of the benzoperimidine family in multidrug resistant cells”, Eur. J. Pharmacol. 413(2-3), 131–141.
   Web of Science ®Google Scholar
• Tmej, C., Chiba, P., Huber, M., Richter, E., Hitzler, M., Schaper, K.J. and Ecker, G. (1998) “A combined Hansch/Free-Wilson approach as predictive tool in QSAR studies on propafenone-type modulators of multidrug resistance”, Arch. Pharm. (Weinheim) 331, 233–240.
   PubMed Web of Science ®Google Scholar
• Tmej, C., Chiba, P., Schaper, K.J., Ecker, G. and Fleischhacker, W. (1999) “Artificial neural networks as versatile tools for prediction of MDR-modulatory activity”, Adv. Exp. Med., Biol. 457, 95–105.
   PubMed Web of Science ®Google Scholar
• Toffoli, G., Simone, F., Corona, G., Raschack, M., Cappelletto, B., Gigante, M. and Boiocchi, M. (1995) “Structure-activity relationship of verapamil analogs and reversal of multidrug resistance”, Biochem. Pharmacol. 50, 1245–1255.
   PubMed Web of Science ®Google Scholar
• Tohda, H., Yasui, A., Yasumoto, T., Nakayasu, M., Shima, H., Nagao, M. and Sugimura, T. (1994) “Chinese hamster ovary cells resistant to okadaic acid express a multidrug resistant phenotype”, Biochem. Biophys. Res. Commun. 203, 1210–1216.
   PubMed Web of Science ®Google Scholar
• Tolle-Sander, S., Rautio, J., Wring, S., Polli, J.W. and Polli, J.E. (2003) “Midazolam exhibits characteristics of a highly permeable P-glyco- protein substrate”, Pharm. Res. 20, 757–764.
   PubMed Web of Science ®Google Scholar
• Uhr, M., Steckler, T., Yassouridis, A. and Holsboer, F. (2000) “Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood– brain barrier deficiency due to mdr1a P-glycoprotein gene disruption”, Neuropsychopharmacology 22, 380– 387.
   PubMed Web of Science ®Google Scholar
• Veber, D.F., Johnson, S.R., Cheng, H.Y., Smith, B.R., Ward, K.W. and Kopple, K.D. (2002) “Molecular properties that influence the oral bioavailability of drug candidates”, J. Med. Chem. 45, 2615–2623.
   PubMed Web of Science ®Google Scholar
• Wacher, V.J., Salphati, L. and Benet, L.Z. (2001) “Active secretion and enterocytic drug metabolism barriers to drug absorption”, Adv. Drug Deliv. Rev. 46, 89–102.
   PubMed Web of Science ®Google Scholar
• Wagner, D., Spahn-Langguth, H., Hanafy, A., Koggel, A. and Langguth, P. (2001) “Intestinal drug efflux: formulation and food effects”, Adv. Drug Deliv. Rev. 50, S13–S31.
   PubMed Web of Science ®Google Scholar
• Wandel, C., Kim, R., Wood, M. and Wood, A. (2002) “Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein”, Anesthesiology 96, 913–920.
   PubMed Web of Science ®Google Scholar
• van De Waterbeemd, H., Smith, D.A., Beaumont, K. and Walker, D.K. (2001) “Property-based design: optimization of drug absorption and pharmacokinetics”, J. Med. Chem. 44, 1313–1333.
   PubMed Web of Science ®Google Scholar
• van de Waterbeemd, H. and Gifford, E. (2003) “ADMET in silico modelling: towards prediction paradise?”, Nat. Rev. Drug Discov. 2, 192–204.
   PubMed Web of Science ®Google Scholar
• Wielinga, P.R., Westerhoff, H.V. and Lankelma, J. (2000) “The relative importance of passive and P-glycoprotein mediated anthracycline efflux from multidrug-resistant cells”, Eur. J. Biochem. 267, 649–657.
   PubMedGoogle Scholar
• Wils, P., Phung-Ba, V., Warnery, A., Lechardeur, D., Raeissi, S., Hidalgo, I.J. and Scherman, D. (1994) “Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers”, Biochem. Pharmacol. 48, 1528–1530.
   PubMed Web of Science ®Google Scholar
• Yamamoto, C., Murakami, H., Koyabu, N., Takanaga, H., Matsuo, H., Uchiumi, T., Kuwano, M., Naito, M., Tsuruo, T., Ohtani, H. and Sawada, Y. (2002) “Contribution of P-glycoprotein to efflux of ramosetron, a 5-HT3 receptor antagonist, across the blood-brain barrier”, J. Pharm. Pharmacol. 54, 1055–1063.
   PubMed Web of Science ®Google Scholar
• Yamazaki, M., Neway, W.E., Ohe, T., Chen, I., Rowe, J.F., Hochman, J.H., Chiba, M. and Lin, J.H. (2001) “In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results”, J. Pharmacol. Exp. Ther. 296, 723–735.
   PubMed Web of Science ®Google Scholar
• Yasuda, K., Lan, L.B., Sanglard, D., Furuya, K., Schuetz, J.D. and Schuetz, E.G. (2002) “Interaction of cytochrome P450 3A inhibitors with P- glycoprotein”, J. Pharmacol. Exp. Ther. 303, 323–332.
   PubMed Web of Science ®Google Scholar
• Young, A.M., Allen, C.E. and Audus, K.L. (2003) “Efflux transporters of the human placenta”, Adv. Drug Deliv. Rev. 55, 125–132.
   PubMed Web of Science ®Google Scholar
• Yu, D.K. (1999) “The contribution of P-glycoprotein to pharmaco- kinetic drug-drug interactions”, J. Clin. Pharmacol. 39, 1203–1211.
   PubMed Web of Science ®Google Scholar
• Yu, E.W., McDermott, G., Zgurskaya, H.I., Nikaido, H. and Koshland, D.E. Jr. (2003) “Structural Basis of multiple drug-binding capacity of the AcrB multidrug efflux pump”, Science 300, 976– 980.
   PubMed Web of Science ®Google Scholar
• Yusa, K. and Tsuruo, T. (1989) “Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glyco- protein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells”, Cancer Res. 49, 5002–5006.
   PubMed Web of Science ®Google Scholar
• Zamora, J.M., Pearce, H.L. and Beck, W.T. (1988) “Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells”, Mol. Pharmacol. 33, 454–462.
   PubMed Web of Science ®Google Scholar
• Zhang, Y. and Benet, L.Z. (1998) “Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers”, Pharm. Res. 15, 1520–1524.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., Guo, X., Lin, E.T. and Benet, L.Z. (1998) “Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor”, Drug Metab. Dispos. 26, 360–366.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., Bachmeier, C. and Miller, D.W. (2003) “In vitro and in vivo models for assessing drug efflux transporter activity”, Adv. Drug Deliv. Rev. 55, 31–51.
   PubMed Web of Science ®Google Scholar
• Zhao, Y.H., Le, J., Abraham, M.H., Hersey, A., Eddershaw, P.J., Luscombe, C.N., Butina, D., Beck, G., Sherborne, B., Cooper, I., Platts, J.A. and Boutina, D. (2001) “Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors”, J. Pharm. Sci. 90, 749–784.
   PubMed Web of Science ®Google Scholar
• Zmuidinavicius, D., Didziapetris, R., Japertas, P., Avdeef, A. and Petrauskas, A. (2003a) “Classification structure-activity relations (C-SAR) in prediction of human intestinal absorption”, J. Pharm. Sci. 92, 621–633.
   PubMed Web of Science ®Google Scholar
• Zmuidinavicius, D., Japertas, P., Petrauskas, A. and Didziapetris, R. (2003b) “Progress in toxinformatics: the challenge of predicting acute toxicity”, Curr. Top. Med. Chem. 3, 1301–1314.
   PubMed Web of Science ®Google Scholar